Do analysts prefer PTHL or SINT?

Sintx Technologies has a consensus price target of $9.33, indicating a potential upside of 391.23%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sintx Technologies is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sintx Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher earnings & valuation, PTHL or SINT?

Pheton has higher earnings, but lower revenue than Sintx Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pheton $305.22K 6.58 -$660K N/A N/A Sintx Technologies $1.02M 8.05 -$10.36M -$5.07 N/A

Do analysts recommend PTHL or NXL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, PTHL or NXL?

Pheton has higher revenue and earnings than Nexalin Technology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pheton $305.22K 6.58 -$660K N/A N/A Nexalin Technology $300K 24.76 -$8.22M -$0.47 N/A

Do analysts rate NDRA or PTHL?

ENDRA Life Sciences currently has a consensus price target of $25.00, indicating a potential upside of 429.66%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, NDRA or PTHL?

Pheton has higher revenue and earnings than ENDRA Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ENDRA Life Sciences N/A N/A -$7.03M -$8.15 N/A Pheton $305.22K 6.58 -$660K N/A N/A

Is NDRA or PTHL more profitable?

Pheton's return on equity of 0.00% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets ENDRA Life Sciences N/A -433.64% -204.58% Pheton N/A N/A N/A

Do analysts prefer PTHL or NVNO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings and valuation, PTHL or NVNO?

Pheton has higher revenue and earnings than enVVeno Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pheton $305.22K 6.58 -$660K N/A N/A enVVeno Medical N/A N/A -$19.47M -$25.54 N/A

Is PTHL or NVNO more profitable?

Pheton's return on equity of 0.00% beat enVVeno Medical's return on equity. Company Net Margins Return on Equity Return on Assets Pheton N/A N/A N/A enVVeno Medical N/A -66.39% -60.42%

Do analysts rate PTHL or QNRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, PTHL or QNRX?

Pheton has higher revenue and earnings than Quoin Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pheton $305.22K 6.58 -$660K N/A N/A Quoin Pharmaceuticals N/A N/A -$15.81M -$29.56 N/A

Is PTHL or QNRX more profitable?

Pheton's return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Pheton N/A N/A N/A Quoin Pharmaceuticals N/A -489.85% -221.29%

Pheton (PTHL) Competitors

$0.31 -0.01 (-2.21%)

As of 07/2/2026

Compare

PTHL vs. SINT, NXL, NDRA, NVNO, and QNRX

Should you buy Pheton stock or one of its competitors? MarketBeat compares Pheton with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pheton include Sintx Technologies (SINT), Nexalin Technology (NXL), ENDRA Life Sciences (NDRA), enVVeno Medical (NVNO), and Quoin Pharmaceuticals (QNRX). These companies are all part of the "medical equipment" industry.

How does Pheton compare to Sintx Technologies?

Pheton (NASDAQ:PTHL) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Pheton has a net margin of 0.00% compared to Sintx Technologies' net margin of -1,058.60%. Pheton's return on equity of 0.00% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
Sintx Technologies	-1,058.60%	-366.49%	-115.04%

Pheton has a beta of 5.4, meaning that its share price is 440% more volatile than the broader market. Comparatively, Sintx Technologies has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

18.4% of Sintx Technologies shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pheton has higher earnings, but lower revenue than Sintx Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	6.58	-$660K	N/A	N/A
Sintx Technologies	$1.02M	8.05	-$10.36M	-$5.07	N/A

In the previous week, Pheton's average media sentiment score of 0.00 equaled Sintx Technologies'average media sentiment score.

Company	Overall Sentiment
Pheton	Neutral
Sintx Technologies	Neutral

Sintx Technologies has a consensus price target of $9.33, indicating a potential upside of 391.23%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sintx Technologies is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Sintx Technologies beats Pheton on 7 of the 12 factors compared between the two stocks.

How does Pheton compare to Nexalin Technology?

Pheton (NASDAQ:PTHL) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pheton has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,018.12%. Pheton's return on equity of 0.00% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

0.7% of Nexalin Technology shares are owned by institutional investors. 25.3% of Nexalin Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Pheton has higher revenue and earnings than Nexalin Technology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	6.58	-$660K	N/A	N/A
Nexalin Technology	$300K	24.76	-$8.22M	-$0.47	N/A

In the previous week, Pheton's average media sentiment score of 0.00 equaled Nexalin Technology'saverage media sentiment score.

Company	Overall Sentiment
Pheton	Neutral
Nexalin Technology	Neutral

Pheton has a beta of 5.4, meaning that its stock price is 440% more volatile than the broader market. Comparatively, Nexalin Technology has a beta of 4, meaning that its stock price is 300% more volatile than the broader market.

Summary

Pheton beats Nexalin Technology on 6 of the 9 factors compared between the two stocks.

How does Pheton compare to ENDRA Life Sciences?

ENDRA Life Sciences (NASDAQ:NDRA) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

ENDRA Life Sciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Pheton has a beta of 5.4, suggesting that its share price is 440% more volatile than the broader market.

Pheton's return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-433.64%	-204.58%
Pheton	N/A	N/A	N/A

Pheton has higher revenue and earnings than ENDRA Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A
Pheton	$305.22K	6.58	-$660K	N/A	N/A

ENDRA Life Sciences currently has a consensus price target of $25.00, indicating a potential upside of 429.66%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of ENDRA Life Sciences shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, ENDRA Life Sciences had 1 more articles in the media than Pheton. MarketBeat recorded 1 mentions for ENDRA Life Sciences and 0 mentions for Pheton. ENDRA Life Sciences' average media sentiment score of 0.00 equaled Pheton'saverage media sentiment score.

Company	Overall Sentiment
ENDRA Life Sciences	Neutral
Pheton	Neutral

Summary

ENDRA Life Sciences beats Pheton on 6 of the 11 factors compared between the two stocks.

How does Pheton compare to enVVeno Medical?

Pheton (NASDAQ:PTHL) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Pheton has higher revenue and earnings than enVVeno Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	6.58	-$660K	N/A	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$25.54	N/A

In the previous week, Pheton's average media sentiment score of 0.00 equaled enVVeno Medical'saverage media sentiment score.

Company	Overall Sentiment
Pheton	Neutral
enVVeno Medical	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Pheton has a beta of 5.4, suggesting that its share price is 440% more volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

34.7% of enVVeno Medical shares are held by institutional investors. 15.0% of enVVeno Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pheton's return on equity of 0.00% beat enVVeno Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
enVVeno Medical	N/A	-66.39%	-60.42%

Summary

Pheton beats enVVeno Medical on 5 of the 8 factors compared between the two stocks.

How does Pheton compare to Quoin Pharmaceuticals?

Pheton (NASDAQ:PTHL) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 13.5% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Pheton has a beta of 5.4, indicating that its share price is 440% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Pheton's return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than Pheton. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 0 mentions for Pheton. Pheton's average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Pheton	Neutral
Quoin Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pheton has higher revenue and earnings than Quoin Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	6.58	-$660K	N/A	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

Summary

Pheton and Quoin Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

Get Pheton News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTHL vs. The Competition

Export

Metric	Pheton	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.01M	$9.63B	$7.16B	$12.48B
Dividend Yield	N/A	1.62%	2.66%	6.52%
P/E Ratio	N/A	27.84	28.02	24.70
Price / Sales	6.58	18.50	540.55	99.42
Price / Cash	N/A	114.69	49.26	57.09
Price / Book	0.32	6.19	10.96	6.46
Net Income	-$660K	$179.69M	$3.57B	$337.01M
7 Day Performance	-0.29%	3.82%	2.12%	1.69%
1 Month Performance	7.05%	10.36%	5.25%	3.81%
1 Year Performance	-98.40%	14.53%	33.29%	23.90%

Pheton Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTHL Pheton	N/A	$0.31 -2.2%	N/A	-98.4%	$2.01M	$305.22K	N/A	11	Gap Down
SINT Sintx Technologies	3.2627 of 5 stars	$1.96 +2.1%	$9.33 +376.2%	-42.9%	$8.29M	$1.02M	N/A	40	Short Interest Decrease
NXL Nexalin Technology	0.4359 of 5 stars	$0.33 -7.0%	N/A	-62.3%	$7.41M	$300K	N/A	3
NDRA ENDRA Life Sciences	2.168 of 5 stars	$6.27 +18.1%	$25.00 +298.7%	+36.6%	$6.74M	N/A	N/A	20	News Coverage High Trading Volume
NVNO enVVeno Medical	1.0824 of 5 stars	$11.57 +18.2%	N/A	-92.1%	$6.54M	N/A	N/A	30	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTHL) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pheton (PTHL) Competitors

PTHL vs. SINT, NXL, NDRA, NVNO, and QNRX

How does Pheton compare to Sintx Technologies?

Summary

How does Pheton compare to Nexalin Technology?

Summary

How does Pheton compare to ENDRA Life Sciences?

Summary

How does Pheton compare to enVVeno Medical?

Summary

How does Pheton compare to Quoin Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTHL vs. The Competition

Pheton Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pheton (PTHL) Competitors

PTHL vs. SINT, NXL, NDRA, NVNO, and QNRX

How does Pheton compare to Sintx Technologies?

Is PTHL or SINT more profitable?

Which has more volatility and risk, PTHL or SINT?

Do institutionals & insiders hold more shares of PTHL or SINT?

Which has higher earnings & valuation, PTHL or SINT?

Does the media favor PTHL or SINT?

Do analysts prefer PTHL or SINT?

Summary

How does Pheton compare to Nexalin Technology?

Do analysts recommend PTHL or NXL?

Is PTHL or NXL more profitable?

Do insiders and institutionals believe in PTHL or NXL?

Which has higher valuation & earnings, PTHL or NXL?

Does the media prefer PTHL or NXL?

Which has more volatility and risk, PTHL or NXL?

Summary

How does Pheton compare to ENDRA Life Sciences?

Which has more volatility and risk, NDRA or PTHL?

Is NDRA or PTHL more profitable?

Which has preferable earnings & valuation, NDRA or PTHL?

Do analysts rate NDRA or PTHL?

Do insiders & institutionals have more ownership in NDRA or PTHL?

Does the media refer more to NDRA or PTHL?

Summary

How does Pheton compare to enVVeno Medical?

Which has better earnings and valuation, PTHL or NVNO?

Does the media prefer PTHL or NVNO?

Do analysts prefer PTHL or NVNO?

Which has more risk and volatility, PTHL or NVNO?

Do insiders and institutionals hold more shares of PTHL or NVNO?

Is PTHL or NVNO more profitable?

Summary

How does Pheton compare to Quoin Pharmaceuticals?

Do insiders and institutionals have more ownership in PTHL or QNRX?

Which has more volatility & risk, PTHL or QNRX?

Is PTHL or QNRX more profitable?

Does the media prefer PTHL or QNRX?

Do analysts rate PTHL or QNRX?

Which has better valuation and earnings, PTHL or QNRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTHL vs. The Competition

Pheton Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools